Literature DB >> 25563632

Long-term results of ethanol sclerotherapy with or without adjunctive surgery for head and neck arteriovenous malformations.

Byungjun Kim1, Keonha Kim, Pyoung Jeon, Sungtae Kim, Hyungjin Kim, Hongsik Byun, Dongik Kim, Youngwook Kim.   

Abstract

INTRODUCTION: Ethanol sclerotherapy has shown favorable short-term efficacy in managing head and neck arteriovenous malformation (AVM) which is well known for high recurrence rate after treatment. The purpose of this study was to report immediate treatment results and long-term follow-up results of ethanol sclerotherapy in patients with head and neck AVMs.
METHODS: We performed a retrospective review of 45 patients with head and neck AVMs treated between April 1997 and December 2013 by using ethanol sclerotherapy with or without adjunctive surgery. The degree of AVM eradication was analyzed, and complications per treatment session were recorded. Long-term treatment effectiveness was assessed with clinical and imaging follow-up.
RESULTS: In total, 132 sclerotherapies were performed in the 45 patients, with a total angiographic eradication rate of 17.8% (n = 8). Partial resolution was achieved in 34 patients, and three patients showed no response. Mean follow-up period was 56.6 months (range, 13-144 months). The long-term recurrence rate was 11.1% (5/45), and all recurrences occurred more than 3 years after the treatment with interval disease-controlled period. The major complication rate was 3.8% (5/132), and 34 minor complications (25.8%) occurred.
CONCLUSIONS: Ethanol sclerotherapy is effective for achieving long-term durable cure of head and neck AVMs. In patients with non-curable disease, it is also effective for symptom palliation and long-term disease control. However, given recurrence after interval disease-controlled period, long-term follow-up should be required to detect recurrence in patients with any residual lesion after treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563632     DOI: 10.1007/s00234-014-1483-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  27 in total

1.  Society of Interventional Radiology clinical practice guidelines.

Authors:  David Sacks; Tricia E McClenny; John F Cardella; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

2.  Craniofacial arteriovenous malformation: preoperative embolization with direct puncture and injection of n-butyl cyanoacrylate.

Authors:  M H Han; S O Seong; H D Kim; K H Chang; K M Yeon; M C Han
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

3.  Arteriovenous malformations of the head and neck: natural history and management.

Authors:  M P Kohout; M Hansen; J J Pribaz; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1998-09       Impact factor: 4.730

4.  Treatment of brain arteriovenous malformations with high-flow arteriovenous fistulas: risk and complications associated with endovascular embolization in multimodality treatment. Clinical article.

Authors:  Ichiro Yuki; Robert H Kim; Gary Duckwiler; Reza Jahan; Satoshi Tateshima; Nestor Gonzalez; Alessandra Gorgulho; Jorge Lee Diaz; Antonio A De Salles; Fernando Viñuela
Journal:  J Neurosurg       Date:  2010-10       Impact factor: 5.115

5.  Ethanol embolization of arteriovenous malformations of the mandible.

Authors:  X D Fan; L X Su; J W Zheng; L Z Zheng; Z Y Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2009-03-06       Impact factor: 3.825

6.  Large arteriovenous malformations of the face: aesthetic results with recurrence control.

Authors:  J P Bradley; B M Zide; A Berenstein; M T Longaker
Journal:  Plast Reconstr Surg       Date:  1999-02       Impact factor: 4.730

7.  Auricular arteriovenous malformations: potential success of superselective ethanol embolotherapy.

Authors:  YunBo Jin; XiaoXi Lin; Hui Chen; XiaoJie Hu; XinDong Fan; Wei Li; Gang Ma; Chuan Yang; Wei Wang
Journal:  J Vasc Interv Radiol       Date:  2009-04-17       Impact factor: 3.464

8.  Serum ethanol levels after alcohol sclerotherapy of arteriovenous malformations.

Authors:  Jeong-Jin Lee; Young-Soo Do; Jie-Ae Kim
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

9.  Management of arteriovenous malformations: a multidisciplinary approach.

Authors:  Byung-Boong Lee; Y S Do; Wayne Yakes; D I Kim; Raul Mattassi; W S Hyon
Journal:  J Vasc Surg       Date:  2004-03       Impact factor: 4.268

10.  Management strategy for facial arteriovenous malformations.

Authors:  P S Bhandari; L P Sadhotra; P Bhargava; A S Bath; M K Mukherjee; Sanjay Maurya
Journal:  Indian J Plast Surg       Date:  2008-07
View more
  6 in total

Review 1.  Venous malformations: clinical diagnosis and treatment.

Authors:  Sasan Behravesh; Wayne Yakes; Nikhil Gupta; Sailendra Naidu; Brian W Chong; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

2.  Interventional therapy of extracranial arteriovenous malformations of the head and neck-A systematic review.

Authors:  Daniel Lilje; Martin Wiesmann; Dimah Hasan; Alexander Riabikin; Hani Ridwan; Frank Hölzle; Omid Nikoubashman
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

3.  Percutaneous Salivary Gland Ablation using Ethanol in a Rat Model.

Authors:  Emma Burch; Lacey Lubeley; James Murakami
Journal:  J Oral Maxillofac Res       Date:  2017-12-31

4.  Ocular infarction following ethanol sclerotherapy of an arteriovenous malformation.

Authors:  Tim Link; Yong Kam; Radwan Ajlan
Journal:  Am J Ophthalmol Case Rep       Date:  2019-04-25

Review 5.  Surgical management of auricular arteriovenous malformations: A literature review.

Authors:  Ruiquan Liu; Jianguo Chen; Litao Jia; Bo Pan; Haiyue Jiang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-03-15

Review 6.  Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis.

Authors:  Daniel Lilje; Martin Wiesmann; Dimah Hasan; Hani Ridwan; Frank Hölzle; Omid Nikoubashman
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.